

Press release from Emotra AB (publ)

Göteborg, October 26, 2020

EMOTRA AB announces the results of the TO 2020 subscription-warrant conversion

Today, October 26, 2020, Emotra AB (“Emotra” or “the Company”) published the results of the TO 2020 series subscription-warrant conversion. These warrants were emitted in the spring of 2020 in connection with Emotra’s rights issue. In the period October 9–23, 2020, owners of subscription warrants in the TO 2020 series were given the opportunity to convert these warrants into regular stock in Emotra AB. In total, 9,615,410 shares were subscribed through the conversion of the same amount of subscription warrants, which equals a conversion rate of approximately 82.5 percent. This conversion will provide Emotra with a cash injection of appr. 3.8 MSEK before issue expenses.

Number of Shares and share capital

This will provide Emotra with approximately 3.8 MSEK before issue expenses, which are estimated to amount to about 0.2 MSEK. When these new shares have been registered at the Swedish Companies Registration Office, the number of outstanding shares in Emotra will increase by 9,615,410, from 38,043,599 to 47,659,009. Also, the Company's share capital will increase by 182,692.79 SEK, from 722,828.381 SEK to 905,521.171 SEK.

For further information about Emotra, please contact:

Daniel Poté, CEO

Telephone: +46 732 34 41 93

E-mail: daniel@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on October 26, 2020, under the above contact’s supervision.

***EMOTRA AB** is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se